Peslie Gibson Ng'ambi

Peslie is a health economist with experience in Heath Technology Assessment (HTA), academia, and medical device industry. He holds a PhD in Health Economics from the University of Manchester, where he focused on quantifying the economic impact of psoriasis in the UK using a mixed methods approach. Through his research, Peslie used routinely collected observational data to estimate costs attributable to psoriasis, conducted two systematic reviews, and critically appraised evidence on the cost and impact of psoriasis on health-related quality of life and well-being. He also holds an MSc in International Pharmacoeconomics and Health Economics from Cardiff University and a Bachelor of Pharmacy from the University of Zambia.

Peslie’s experience includes work as a research associate at the University of Manchester, where he led the economic evaluation of a virtual one-stop clinic for eye cancers and supported medical device companies with economic evidence generation. He also built early economic evaluation models of diagnostic tests to aid in early diagnosis.

Peslie also served as a Lecturer on an MSc International Health Economics and Pharmacoeconomics at Hochschule Fresenius in Germany teaching Economic Evaluation and Modelling. He has also supervised student dissertations focusing partition survival analysis and Markov modelling to evaluate oncology drugs and drug-eluting stents.

Peslie began his began his career as a pharmacist in Zambia, where he worked in retail, hospital and administration pharmacy responsible for pharmaceutical management, monitoring and evaluation, budgeting, and capacity building in pharmaceutical services.

Peslie completed a PhD in Health Economics which focused on quantifying the economic impact of psoriasis as part of the Global Psoriasis Atlas. Understanding the economic burden of this disease entails understanding and valuing productivity loss, incremental healthcare costs, health related quality of life and well-being. This involves taking a more pragmatic societal perspective in valuing health and ultimately the value of current and future treatment investments. Impact of psoriasis on productivity will be explored and several methods used to value it in terms of presenteeism, absenteeism and unemployment

Prior to his PhD research, he worked on the economic evaluation of a National Institute of Health Research (NIHR) for Patient Benefit funded study that was evaluating a one-stop eye clinic for people who referred from opticians with lesions (Choroidal Nevomelanocytic Lessions), generally benign, at the back of the eye. He also worked on a number of studies as part of the Manchester Molecular Pathology Innovation Center (MMPATHIC http://www.biomarkers.manchester.ac.uk/about/mmpathic/) such as the economic evaluation of the Ultra-sensitive Cardiac Troponin I (cTnI) for risk stratification, Rule-out, and therapy guidance

Peslie holds a Master of Science in International Pharmacoeconomics and Health Economics from Cardiff University, UK and Bachelor of Pharmacy from The University of Zambia, Zambia. Over the years, he  has worked as a Pharmacist and Health Economist. His experience spans the hospital, pharmaceutical and medical device industry on international projects in Health Economic Evaluation, Market Access, and Reimbursement for healthcare products. He is currently part of the Precision Medicine Economics Team (PMET) of the Manchester Centre for Health Economics. PMET is focused on the Economics of Precision medicine within healthcare.

He holds an external Lecturer position at Fresenius University of Applied Science in Germany where he teaches Economic evaluation and Decision Analytic Modelling to Masters students.